Logo image of YMTX

YUMANITY THERAPEUTICS INC (YMTX) Stock Fundamental Analysis

NASDAQ:YMTX - Nasdaq - US98872L1026 - Common Stock - Currency: USD

1.89  +0.15 (+8.62%)

After market: 1.9 +0.01 (+0.53%)

Fundamental Rating

1

YMTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While YMTX seems to be doing ok healthwise, there are quite some concerns on its profitability. YMTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

YMTX had negative earnings in the past year.
In the past year YMTX has reported a negative cash flow from operations.
YMTX Yearly Net Income VS EBIT VS OCF VS FCFYMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

YMTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YMTX Yearly ROA, ROE, ROICYMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300 -400 -500

1.3 Margins

YMTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YMTX Yearly Profit, Operating, Gross MarginsYMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

YMTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for YMTX has been increased compared to 1 year ago.
YMTX has a worse debt/assets ratio than last year.
YMTX Yearly Shares OutstandingYMTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
YMTX Yearly Total Debt VS Total AssetsYMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

YMTX has an Altman-Z score of -35.79. This is a bad value and indicates that YMTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -35.79, YMTX is doing worse than 94.38% of the companies in the same industry.
YMTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.79
ROIC/WACCN/A
WACC9.55%
YMTX Yearly LT Debt VS Equity VS FCFYMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

YMTX has a Current Ratio of 2.21. This indicates that YMTX is financially healthy and has no problem in meeting its short term obligations.
YMTX has a worse Current ratio (2.21) than 80.97% of its industry peers.
A Quick Ratio of 2.21 indicates that YMTX has no problem at all paying its short term obligations.
YMTX has a worse Quick ratio (2.21) than 79.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
YMTX Yearly Current Assets VS Current LiabilitesYMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

YMTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -337.84%.
Looking at the last year, YMTX shows a very negative growth in Revenue. The Revenue has decreased by -65.84% in the last year.
The Revenue has been decreasing by -0.82% on average over the past years.
EPS 1Y (TTM)-337.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.04%
Revenue 1Y (TTM)-65.84%
Revenue growth 3Y41.49%
Revenue growth 5Y-0.82%
Sales Q2Q%-14.25%

3.2 Future

YMTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.21% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-60.56%
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%
EPS Next 5Y4.21%
Revenue Next Year9.96%
Revenue Next 2Y14.87%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
YMTX Yearly Revenue VS EstimatesYMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
YMTX Yearly EPS VS EstimatesYMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YMTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YMTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMTX Price Earnings VS Forward Price EarningsYMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMTX Per share dataYMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

YMTX's earnings are expected to decrease with -27.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%

More info and screens

0

5. Dividend

5.1 Amount

YMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

YUMANITY THERAPEUTICS INC

NASDAQ:YMTX (12/16/2022, 8:00:02 PM)

After market: 1.9 +0.01 (+0.53%)

1.89

+0.15 (+8.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-22 2023-03-22
Inst Owners0%
Inst Owner Change0%
Ins Owners7.84%
Ins Owner Change0%
Market Cap20.52M
Analysts84.44
Price Target35.7 (1788.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.65%
Min EPS beat(2)55.44%
Max EPS beat(2)71.86%
EPS beat(4)4
Avg EPS beat(4)35.85%
Min EPS beat(4)6.92%
Max EPS beat(4)71.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-40.02%
Min Revenue beat(2)-45.02%
Max Revenue beat(2)-35.02%
Revenue beat(4)0
Avg Revenue beat(4)-47.13%
Min Revenue beat(4)-58.63%
Max Revenue beat(4)-35.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-45.33%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.24
P/FCF N/A
P/OCF N/A
P/B 3.75
P/tB 3.75
EV/EBITDA N/A
EPS(TTM)-2.64
EYN/A
EPS(NY)-9.8
Fwd EYN/A
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.35
OCFYN/A
SpS0.45
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -35.79
F-Score3
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)18.35%
Cap/Depr(5y)17.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-337.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.04%
EPS Next Y-60.56%
EPS Next 2Y-59.53%
EPS Next 3Y-27.59%
EPS Next 5Y4.21%
Revenue 1Y (TTM)-65.84%
Revenue growth 3Y41.49%
Revenue growth 5Y-0.82%
Sales Q2Q%-14.25%
Revenue Next Year9.96%
Revenue Next 2Y14.87%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y52.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.46%
OCF growth 3YN/A
OCF growth 5YN/A